LEN vs REGN
LEN (LEN) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
LEN does not have a complete income-statement cache yet.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
LEN currently screens at market cap $0. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the LEN and REGN stock pages for the full models.
Not investment advice.